A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

INTRODUCTION: The purpose of this analysis was to determine the potential efficacy of recombinant human tissue factor pathway inhibitor (tifacogin) in a subpopulation of patients with community-acquired pneumonia (CAP) from a phase III study of severe sepsis. METHODS: A retrospective review of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Laterre, Pierre-François, Opal, Steven M, Abraham, Edward, LaRosa, Steven P, Creasey, Abla A, Xie, Fang, Poole, Lona, Wunderink, Richard G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689471/
https://www.ncbi.nlm.nih.gov/pubmed/19284881
http://dx.doi.org/10.1186/cc7747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689471/
https://www.ncbi.nlm.nih.gov/pubmed/19284881
http://dx.doi.org/10.1186/cc7747

Ejemplares similares